Streetbeat News

Stock Prices

AZN

NVO

VANI

Vivani Medical (NASDAQ:VANI) reported positive preclinical results for its exenatide implant, showing significant liver fat reduction in obese mice. The implant, which could be a promising treatment for obesity, is set to begin clinical trials in late 2024. The news led to a 7.32% increase in VANI's stock price.

Portfolio Pulse from Vandana Singh

September 04, 2024 | 11:33 am

VANI

Vivani Medical announced that its GLP-1 (exenatide) implant achieved an 82% reduction in liver fat in an obese mouse model with a single administration, suggesting potential for twice-yearly dosing.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 11:30 am

APH

Amphenol's stock is experiencing a decline following a downgrade by B of A Securities from Buy to Neutral, with a reduced price target from $80 to $71.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 11:30 am

NVDA

SPY

USO

U.S. stocks experienced a significant decline, with the S&P 500, Nasdaq, and Dow seeing their steepest losses since early August. Nvidia's sharp drop of nearly 10% contributed to the broader market decline. Weaker manufacturing data and uncertainty over Federal Reserve interest rate cuts dampened investor sentiment. Most S&P 500 sectors fell, particularly energy, tech, and communication services, while real estate and consumer staples gained. Asian and European markets also saw declines, and crude oil prices fell below $70.

Portfolio Pulse from Akanksha Bakshi

September 04, 2024 | 11:26 am

HRL

Hormel Foods Corporation (NYSE:HRL) revised its FY24 outlook due to production disruptions, causing its stock to drop. Despite beating EPS estimates, sales missed expectations, and the company faces challenges in its Retail and International segments. Hormel anticipates continued growth in its Foodservice segment and improvements in its supply chain.

Portfolio Pulse from Nabaparna Bhattacharya

September 04, 2024 | 11:25 am

TSLA

Tesla enthusiasts drove Cybertrucks from Florida to the Arctic Ocean, showcasing the vehicle's capabilities. Despite the Cybertruck's range limitations, Tesla plans to offer a range extender and ramp up production. The journey highlights Tesla's commitment to innovation and customer engagement.

Portfolio Pulse from Anan Ashraf

September 04, 2024 | 11:17 am

IVVD

Invivyd has commenced dosing in a Phase 1 clinical trial for VYD2311, a new monoclonal antibody candidate for COVID-19. This marks a significant step in the development of potential treatments for the virus.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 11:16 am

ELDN

Eledon Pharmaceuticals has completed enrollment for its Phase 2 BESTOW clinical trial, which focuses on preventing organ rejection in kidney transplant patients.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 11:10 am

CURV

Torrid Holdings reported Q2 earnings per share of $0.08, beating estimates of $0.06, but sales of $284.64 million slightly missed the $285.37 million estimate. This represents a 33.33% increase in EPS and a 1.56% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 11:04 am

DKS

DICK'S Sporting Goods has raised its full-year 2024 EPS guidance to a range of $13.55 to $13.90, up from the previous range of $13.35 to $13.75, and above the consensus estimate of $13.79.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 11:04 am